NGSgo-ProntoFlex DQA1/DQB1 duplex genotyping assay
Celiac disease is associated with certain HLA-DQA1 and HLA-DQB1 loci. At GenDx, we are developing NGSgo-ProntoFlex DQA1/DQB1, an assay which is compatible with Oxford Nanopore Technologies and Illumina sequencing devices. This duplex assay is designed to amplify both HLA-DQA1 and HLA-DQB1 in the same reaction, making it faster and more efficient to study both genes together.
Celiac disease is an immune-mediated disorder triggered by gluten ingestion in genetically susceptible individuals. It is strongly associated with specific alleles of the HLA-DQA1 and HLA-DQB1 genes, which encode the alpha and beta chains of the HLA-DQ heterodimer. This heterodimer is involved in presenting gluten-derived peptides to T cells, a key step in the immune response leading to the characteristic intestinal damage seen in celiac disease.
Identify genetic risk for celiac disease with high-resolution typing of HLA-DQA and HLA-DQB loci.
To support research in this area, in GenDx we are developing NGSgo-ProntoFlex DQA1/DQB1, a duplex assay that enables whole-gene coverage of both loci in a single workflow. This upcoming assay is designed to be compatible with both Oxford Nanopore Technologies and Illumina sequencing platforms, offering flexible integration into existing sequencing pipelines.
Key features
Whole-gene coverage of both DQA1 and DQB1 loci
Duplex design: genotype both genes in a single reaction
96-sample throughput per run
Same-day results when using Oxford Nanopore Technologies platforms
Compatible with both Oxford Nanopore Technologies and Illumina sequencing platforms
Whether you prefer long-read or short-read sequencing, this assay integrates seamlessly into your workflow, delivering high-quality data with rapid turnaround.
Currently in development.
Want to stay informed? Fill in this form or contact your Sales representative for more information.
